Immunovant, Inc. IMVT
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +14.75%
- 1 year
- +17.53%
- Open
- 29.49
- Prev close
- 29.64
- Mkt cap
- 6.03B
- Vol
- 1.17M
- Avg vol
- 1.35M
- EPS
- -2.82
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 28.76
- High
- 29.78
- Forward P/E
- -10.61
- Beta
- 0.84
- Short ratio
- 10.91
- Inst. own
- 54.75%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 9, 2026
- 50-d avg
- 34.86
- 200-d avg
- 32.03
- 1y target
- 48.88
5D chart
Signals (95)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 29, 3:50 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:50 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:35 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:30 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:30 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 3:05 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:50 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:45 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:10 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:10 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:05 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:05 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 1:45 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:40 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:35 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:20 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:55 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 12:55 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:45 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:00 PM | 3 days ago |
| SMA: Bullish | Oct 29, 11:55 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:35 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:20 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:20 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:15 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:45 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:45 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:10 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:05 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 3:35 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:25 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:05 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 3:05 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:00 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:55 PM | 4 days ago |
| RSI: Overbought | Oct 28, 2:40 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:15 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:15 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:30 PM | 4 days ago |
| SMA: Bearish | Oct 28, 11:25 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:25 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 10:00 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:55 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:55 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:45 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:45 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:35 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 9:35 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 4 days ago |
| RSI: Overbought | Oct 27, 3:45 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:30 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:25 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:20 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:35 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:20 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:35 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:20 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:15 PM | 5 days ago |
| SMA: Bullish | Oct 27, 11:50 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:25 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:20 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:05 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:05 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:00 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:55 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:35 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:35 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 5 days ago |
| SMA: Bullish | Oct 26, 3:55 PM | 5 days ago |
| SMA: Bearish | Oct 26, 3:50 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:45 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:25 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:15 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:30 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:20 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:15 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:15 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:10 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:10 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:05 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:00 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:50 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:45 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:35 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 1:15 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:30 PM | 6 days ago |
| SMA: Bullish | Oct 26, 11:05 AM | 6 days ago |
News
1 week ago globenewswire.com
Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026
DURHAM, N.C., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) today announced that it will report its financial results for the second fiscal quarter ended September 30, 2026 on…
2 weeks ago benzinga.com
Immunovant Q1 2027 Earnings Call: Complete Transcript
Immunovant (NASDAQ:IMVT) held its first-quarter earnings conference call on Thursday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call…
2 weeks ago gurufocus.com
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law FirmPR NewswireNEW YORK, Oct. 12, 2026NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Kuehn Law, PLLC,
2 weeks ago prnewswire.com
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm
NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Immunovant, Inc. (NASDAQ: IMVT) breached their…
2 weeks ago gurufocus.com
IMVT Investors with $100,000 in Losses Have Opportunity to Join Immunovant, Inc. Fraud Investigation with SBS Law
[url="]Schall, Brown and Schwartz[/url] LLP (âSBSâ), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of inv
2 weeks ago businesswire.com
IMVT Investors with $100,000 in Losses Have Opportunity to Join Immunovant, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $IMVT--IMVT Investors with $100,000 in Losses Have Opportunity to Join Immunovant, Inc. Fraud Investigation with SBS Law.
3 weeks ago benzinga.com
Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
U.S. stock futures fell, with Dow futures down 450 points. Argenx sank 8.7% after a Sjögren’s trial was halted for futility; others also slid.
3 weeks ago benzinga.com
Why Applied Digital Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Applied Digital shares rise after Q1 revenue and loss beat estimates; Xiao-I and iPower lead gainers, while China SXT and Medicus Pharma fall.
1 month ago gurufocus.com
Immunovant Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Immunovant (IMVT)
Immunovant Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Immunovant (IMVT)PR NewswireNEW YORK, Sept. 25, 2026Immunovant stock
1 month ago prnewswire.com
Immunovant Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Immunovant (IMVT)
Immunovant stock fell roughly 6% to a more-than-three-month low on September 23, 2026 after the IMVT-1402 cutaneous lupus study missed its primary endpoint. SueWallSt notifies investors of a pending…
1 month ago zacks.com
IMVT Ends Cutaneous Lupus Erythematosus Program, Stock Down
Immunovant's IMVT-1402 misses its primary CLE goal, prompting the company to halt the program despite positive trends and a favorable safety profile.
1 month ago benzinga.com
Immunovant Ends Autoimmune Skin Disorder Program
Immunovant halts IMVT-1402 CLE trial after missing primary endpoints, driving IMVT and Roivant shares down in premarket trading.
-
1 month ago benzinga.com
Roivant And Immunovant Say Topline Results From Period 1 Of Proof-of-concept Trial of IMVT-1402 (Imeroprubart) For Cutaneous Lupus Erythematosus Did Not Achieve Statistical Significance On The Primary Endpoint
Immunovant’s proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus…
1 month ago globenewswire.com
Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
Immunovant's proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus…
1 month ago globenewswire.com
Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
Immunovant's proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus…
1 month ago benzinga.com
Immunovant Q1 2027 Earnings Call: Complete Transcript
On Thursday, Immunovant (NASDAQ:IMVT) discussed first-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by Benzinga APIs.…
2 months ago defenseworld.net
Algert Global LLC Raises Position in Immunovant, Inc. $IMVT
Algert Global LLC increased its stake in Immunovant, Inc. (NASDAQ: IMVT) by 51.1% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional…
2 months ago prnewswire.com
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm
NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Immunovant, Inc. (NASDAQ: IMVT) breached their…
2 months ago defenseworld.net
Immunovant (NASDAQ:IMVT) Sets New 12-Month High – Still a Buy?
Shares of Immunovant, Inc. (NASDAQ: IMVT - Get Free Report) reached a new 52-week high during mid-day trading on Tuesday. The company traded as high as $43.89 and last traded at $43.71, with a volume…
2 months ago seekingalpha.com
Immunovant, Inc. (IMVT) Q1 2027 Earnings Call Transcript
Immunovant, Inc. (IMVT) Q1 2027 Earnings Call Transcript
2 months ago marketbeat.com
Immunovant Q1 Earnings Call Highlights
Roivant said its first quarter was relatively quiet operationally but positioned the company for a more active second half of 2026, with a potential launch of brepocitinib in dermatomyositis,…
2 months ago zacks.com
Immunovant's Q1 Loss Wider Than Expected, Pipeline in Progress
IMVT posts a wider quarterly loss as R&D spending rises, but its cash runway supports IMVT-1402 through a planned Graves' disease commercial launch.
-
2 months ago benzinga.com
Immunovant Q1 EPS $(0.75) Misses $(0.61) Estimate
Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.61) by 22.95 percent. This is a 5.63 percent decrease over losses of $(0.71)…
2 months ago globenewswire.com
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026
All IMVT-1402 clinical development timelines remain on track, including ongoing studies in Graves' disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP),…
-
2 months ago benzinga.com
JP Morgan Maintains Overweight on Immunovant, Raises Price Target to $50
JP Morgan analyst Brian Cheng maintains Immunovant (NASDAQ:IMVT) with a Overweight and raises the price target from $47 to $50.
3 months ago seekingalpha.com
Immunovant: Risk-Reward Set-Up Compelling, Initiating With A Speculative Buy
I initiate coverage of Immunovant with a BUY rating and a $50 price target, driven by optimism around IMVT-1402's differentiated profile. IMVT-1402 demonstrates strong IgG reduction with minimal…
3 months ago globenewswire.com
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm
NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Immunovant, Inc. (NASDAQ: IMVT) breached…
-
4 months ago benzinga.com
Citigroup Maintains Buy on Immunovant, Raises Price Target to $61
Citigroup analyst Samantha Semenkow maintains Immunovant (NASDAQ:IMVT) with a Buy and raises the price target from $57 to $61.
4 months ago zacks.com
Immunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue?
Immunovant (IMVT) reported earnings 30 days ago. What's next for the stock?
5 months ago benzinga.com
CrowdStrike To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday
Wall Street analysts changed outlook on top names. Guggenheim raised price target for IMVT, Piper Sandler increased price target for TRV, and more.
-
5 months ago benzinga.com
Guggenheim Maintains Buy on Immunovant, Raises Price Target to $62
Guggenheim analyst Yatin Suneja maintains Immunovant (NASDAQ:IMVT) with a Buy and raises the price target from $44 to $62.
-
5 months ago benzinga.com
Truist Securities Maintains Hold on Immunovant, Raises Price Target to $30
Truist Securities analyst Danielle Brill maintains Immunovant (NASDAQ:IMVT) with a Hold and raises the price target from $23 to $30.
5 months ago benzinga.com
These Analysts Increase Their Forecasts On Immunovant After Q4 Results
Immunovant (NASDAQ:IMVT) reported a Q4 loss of 73 cents/share, missing estimates of 60 cents. R&D expenses rose to $142.3 million. Analysts adjust price targets.
-
5 months ago benzinga.com
B of A Securities Maintains Buy on Immunovant, Raises Price Target to $43
B of A Securities analyst Jason Gerberry maintains Immunovant (NASDAQ:IMVT) with a Buy and raises the price target from $32 to $43.
-
5 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Immunovant, Raises Price Target to $40
HC Wainwright & Co. analyst Douglas Tsao maintains Immunovant (NASDAQ:IMVT) with a Buy and raises the price target from $35 to $40.
5 months ago benzinga.com
Immunovant Stock Surges Despite Disappointing Earnings Miss
Immunovant Inc (NASDAQ: IMVT) shares are trading higher Wednesday despite posting a wider-than-expected fourth‑quarter loss.
5 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
5 months ago benzinga.com
Crude Oil Down 5%; Lowe's Posts Upbeat Earnings
US stocks rise with Dow gaining 1% on Wednesday. The Nasdaq and S&P 500 also saw gains. Lowe's Companies reported upbeat earnings.
5 months ago benzinga.com
TAT Technologies Posts Upbeat Q1 Earnings, Joins Roivant Sciences, Immunitybio And Other Big Stocks Moving Higher On Wednesday
TAT Technologies Ltd (TATT) reported better-than-expected Q1 results, sending shares up 11.7%. Other big gainers include IMVT, SLS, TE, VUZI, ROIV, POET, ARM, AMC, ALAB, DSGN, and TLN.
5 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
-
5 months ago benzinga.com
Immunovant Q4 EPS $(0.73) Misses $(0.60) Estimate
Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.60) by 21.67 percent. This is a 14.06 percent decrease over losses of…
-
6 months ago benzinga.com
Goldman Sachs Maintains Neutral on Immunovant, Raises Price Target to $32
Goldman Sachs analyst Corinne Johnson maintains Immunovant (NASDAQ:IMVT) with a Neutral and raises the price target from $29 to $32.
7 months ago benzinga.com
Alto Neuroscience, Immunovant And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Dow futures down 400 points, Alto Neuroscience shares dip 13.6% after Phase 2 trial results, other stocks also falling in pre-market trading.
-
7 months ago benzinga.com
Market-Moving News for April 2nd
GSAT: 24% | Globalstar shares are trading higher following reports suggesting that Amazon is in discussions to acquire the company. IMVT: -17% | Immunovant shares are trading lower after the company
7 months ago benzinga.com
Why Globalstar Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Amazon may acquire Globalstar Inc., shares soared in pre-market trading. Other gainers include Turbo Energy SA, Semilux International Ltd, Visionary Holdings Inc, and more. Losers are PMGC Holdings…
-
7 months ago benzinga.com
Immunovant's Phase 3 Batoclimab Studies Each Fail To Meet Primary Proptosis Responder Rate Endpoint In Thyroid Eye Disease
Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findingsPatients in the TED studies demonstrated…
-
8 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Immunovant, Maintains $35 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Immunovant (NASDAQ:IMVT) with a Buy and maintains $35 price target.
-
8 months ago benzinga.com
Guggenheim Maintains Buy on Immunovant, Raises Price Target to $44
Guggenheim analyst Yatin Suneja maintains Immunovant (NASDAQ:IMVT) with a Buy and raises the price target from $41 to $44.
-
8 months ago benzinga.com
Immunovant Q3 EPS $(0.61) Beats $(0.71) Estimate
Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.61) per share which beat the analyst consensus estimate of $(0.71) by 13.72 percent. This is a 19.74 percent increase over losses of $(0.76)…